Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid (original) (raw)

References

• Browne, W. L., Wilson, W. R., Rutland, M., Baguley, B. C. & Ching, L-M (1998). Suppression of serum tumour necrosis factor-α by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res 18: 4409–4414.
  CAS PubMed Google Scholar
• Burroughs, M. H., Tsenova-Berkova, L., Sokol, K., Ossig, J., Tuomanen, E. & Kaplan, G. (1995). Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis. Microb Pathogen 19: 245–255.
  Article CAS Google Scholar
• Carlesimo, M., Giustini, S., Rossi, A., Bonaccorsi, P. & Calvieri, S. (1995). Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32: 866–869.
  Article CAS Google Scholar
• Casini, G. & Ferappi, M. (1964). Preparation of one optical antipode of 2-phthalimidoglutarimide. Farmaco 19: 563–565.
  CAS Google Scholar
• Ching, L. M., Joseph, W. R., Zhuang, L., Atwell, G. J., Rewcastle, G. R., Denny, W. A. & Baguley, B. C. (1991). Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with anti-tumour activity. Eur J Cancer 27: 79–83.
  Article CAS Google Scholar
• Ching, L. M., Joseph, W. R. & Baguley, B. C. (1992). Anti-tumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128–130.
  Article CAS Google Scholar
• Ching, L. M., Joseph, W. R., Crosier, K. E. & Baguley, B. C. (1994a). Induction of tumour necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54: 870–872.
  CAS PubMed Google Scholar
• Ching, L. M., Joseph, W. R., Zhuang, L. & Baguley, B. C. (1994b). Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of Colon 38 tumours. Cancer Chemother Pharmacol 35: 153–160.
  Article CAS Google Scholar
• Ching, L. M., Xu, Z-F, Gummer, B. H., Palmer, B. D., Joseph, W. R. & Baguley, B. C. (1995). Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72: 339–343.
  Article CAS Google Scholar
• Ching, L. M., Browne, W. L., Tchernegovski, R., Gregory, T., Baguley, B. C. & Palmer, B. D. (1998). Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity. Br J Cancer 78: 336–343.
  Article CAS Google Scholar
• D’Amato, R. J., Loughnan, M. S., Flynn, E. & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085.
  Article Google Scholar
• Fabro, S., Smith, R. L. & Williams, R. T. (1967). Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215: 296
  Article CAS Google Scholar
• Gardner-Medwin, J. M., Smith, N. J. & Powell, R. J. (1994). Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet’s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53: 828–832.
  Article CAS Google Scholar
• Gutierrez-Rodriguez, O., Starusta-Bacal, P. & Gutierrez-Montes, O. (1989). Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 16: 158–163.
  CAS PubMed Google Scholar
• Han, J., Thompson, P. & Beutler, B. (1990). Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172: 391–394.
  Article CAS Google Scholar
• Haslett, P. A. J., Corral, L. G., Albert, M. & Kaplan, G. (1998). Thalidomide costimulates primary human t lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the cd8+ subset. J Exp Med 187: 1885–1892.
  Article CAS Google Scholar
• Hogan, M. M. & Vogel, S. N. (1990). Measurement of tumor necrosis factor alpha and beta. In Current Protocols in Immunology, Vol. 1, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W (eds), p. 6.10.1. Greene Publishing Associates and Wiley Interscience: New York
  Google Scholar
• Joseph, W. R., Cao, Z., Mountjoy, K. G., Marshall, E. S., Baguley, B. C. & Ching, L. M. (1999). Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59: 633–638.
  CAS PubMed Google Scholar
• Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J. & Wilson, W. R. (1998). Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanethenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439–445.
  Article CAS Google Scholar
• Mahadevan, V., Malik, S. T. A., Meager, A., Fiers, W., Lewis, G. P. & Hart, I. R. (1990). Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 50: 5537–5542.
  CAS PubMed Google Scholar
• Makonkawkeyoon, S., Limson-Pobre, R. N. R., Moreira, A. L., Schauf, V. & Kaplan, G. (1993). Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90: 5974–5978.
  Article CAS Google Scholar
• Miyachi, H., Azuma, A., Hioki, E., Iwasaki, S., Kobayashi, Y. & Hashimoto, Y. (1996). Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem Biophys Res Commun 224: 426–430.
  Article CAS Google Scholar
• Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A. & Kaplan, G. (1993). Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675–1680.
  Article CAS Google Scholar
• Moreira, A. L., Corral, L. G., Ye, W., Johnson, B., Stirling, D., Muller, G. W., Freedman, V. H. & Kaplan, G. (1997). Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 13: 857–863.
  Article CAS Google Scholar
• Patel, S., Parkin, S. M. & Bibby, M. C. (1997). The effect of 5,6-dimethylxanthenone- 4-acetic acid on tumor necrosis factor production by human immune cells. Anticancer Res 17: 141–150.
  CAS PubMed Google Scholar
• Philpott, M., Baguley, B. C. & Ching, L-M (1995). Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143–148.
  Article CAS Google Scholar
• Philpott, M., Joseph, W. R., Crosier, K. E., Baguley, B. C. & Ching, L. M. (1997). Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76: 1586–1591.
  Article CAS Google Scholar
• Pratesi, G., Rodolfo, M., Rovetta, G. & Parmiani, G. (1990). Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 26: 1079–1083.
  Article CAS Google Scholar
• Rewcastle, G. W., Atwell, G. J., Zhuang, L., Baguley, B. C. & Denny, W. A. (1991). Potential antitumor agents. 61. Structure–activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217–222.
  Article CAS Google Scholar
• Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A. & Kaplan, G. (1991). Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med 173: 699–703.
  Article CAS Google Scholar
• Shakhov, A. N., Collart, M. A., Vassalli, P., Nedospasov, S. A. & Jongeneel, C. V. (1990). Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171: 35–47.
  Article CAS Google Scholar
• Shannon, E. J. & Sandoval, F. (1996). Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 18: 59–72.
  Article CAS Google Scholar
• Shannon, E. J., Howe, R. C., McLean, K. & Hastings, R. C. (1994). Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential. Immunopharmacol Immunotoxicol 16: 717–729.
  Article CAS Google Scholar
• Sheskin, J. (1965). Further observation with thalidomide in lepra reactions. Leprosy Rev 36: 183–187.
  Article CAS Google Scholar
• Silva, S. R. B., Viana, P. C. F., Lugon, N. V., Hoette, M., Ruzany, F. & Lugon, J. R. (1994). Thalidomide for the treatment of uremic pruritus: a crossover randomised double-blind trial. Life Sci 31: 270–273.
  Google Scholar
• Teicher, B. A., Sotomayor, E. A. & Huang, Z. D. (1992). Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702–6704.
  CAS PubMed Google Scholar
• Turk, B. E., Jiang, H. & Liu, J. O. (1996). Binding of thalidomide to alpha(1)-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 93: 7552–7556.
  Article CAS Google Scholar
• Uthoff, K., Zehr, K. J., Gaudin, P. B., Kumar, P., Cho, P. W., Vogelsang, G., Hruban, R. H., Baumgartner, W. A. & Stuart, R. S. (1995). Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorac Surg 59: 277–282.
  Article CAS Google Scholar
• Vogelsang, G. B., Santos, G. W., Colvin, O. M. & Chen, T. (1988). Thalidomide for graft-versus-host disease. Lancet 1: 827
  Article CAS Google Scholar
• Vogelsang, G. B., Farmer, E. R., Hess, A. D., Altamonte, V., Beschorner, W. E., Jabs, D. A., Corio, R. L., Levin, L. S., Colvin, O. M., Wingard, J. R. & Santos, G. W. (1992). Thalidomide for the treatment of chronic graft-versus-host disease. New England J Med 326: 1055–1058.
  Article CAS Google Scholar
• Yang, D., Satoh, M., Ueda, H., Tsukagoshi, S. & Yamazaki, M. (1994). Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 38: 287–293.
  Article CAS Google Scholar
• Zwi, L. J., Baguley, B. C., Gavin, J. B. & Wilson, W. R. (1994). Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79–85.
  CAS PubMed Google Scholar

Download references